

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MEGA MEDICAL TECHNOLOGY LIMITED**

**美加醫學科技有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 876)**

### **PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the Shareholders and potential investors that, based on the preliminary assessment of the information currently available to the Board, the Group is expected to record a loss for the year ended 31 December 2016 notwithstanding there was a profit attributable to the owners of the Company of HK\$9.5 million for the first half of 2016 (i.e., the six months ended 30 June 2016). It is expected that the loss attributable to the owners of the Company for the year ended 31 December 2016 is moderately (more or less halfway) lower than the loss attributable to the owners of the Company for the year ended 31 December 2015 of approximately HK\$30.6 million.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by Mega Medical Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited management accounts of the Group and information currently available to the Board, the Group is expected to record a loss for the year ended 31 December 2016 notwithstanding there was a profit attributable to the owners of the Company of HK\$9.5 million for the first half of 2016 (i.e., the six months ended 30 June 2016). It is expected that the loss attributable to the owners of the Company for the year ended 31 December 2016 is moderately (more or less halfway) lower than the loss attributable to the owners of the Company for the year ended 31 December 2015 of approximately HK\$30.6 million and is a combined effects of the additional expenditure incurred as a result of the discontinuation of the electronic manufacturing service business and the share option expense set off by the profit generated from the dental prosthetics business.

The information contained in this announcement is only based on a preliminary review by the Group’s management on the preliminary management accounts of the Group and the information currently available, which have not been reviewed or audited by the auditors of the Company, and is subject to possible adjustments following further internal review.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Mega Medical Technology Limited**  
**Luo Jun**  
*Chairman*

Hong Kong, 23 January 2017

*As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Luo Jun (Chairman), Mr. Wu Tianyu (Chief Executive Officer) and Mr. Wu Xiaolin, two non-executive Directors, namely, Dr. Jiang Feng and Mr. Xu Hao, and three independent non-executive Directors, namely Dr. Liu Yanwen, Mr. Song Qun and Mr. Guo Peineng.*